Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on October 4, 2021.
NurPhoto | NurPhoto | Getty Images
Merck on Thursday reported first-quarter revenue that fell 9% from the same period a year ago largely due to a steep drop in sales of its Covid antiviral treatment molnupiravir.
Sales of molnupiravir plunged to $392 million during the period, down 88% from the $3.2 billion reported in the first quarter of 2022. Merck said the decrease is primarily the result of lower sales in the U.S., U.K., Japan and Australia.
The company reported total revenue of $14.5 billion during the quarter, down nearly $1.5 billion from the same period a year ago. But excluding the Covid drug, Merck said its revenue grew 11%.
Here’s what Merck reported compared with Wall Street’s expectations, based on a survey of analysts by Refinitiv:
- Earnings per share: $1.40 adjusted, vs. $1.32 expected
- Revenue: $14.49 billion, vs. $13.78 billion expected
The pharmaceutical giant posted a net income of $2.82 billion, or $1.11 per share. That compares with a net income of $4.31 billion, or $1.70 per share, for the same period a year ago. Excluding certain items, Merck’s adjusted earnings per share were $1.40 for the period.
The Rahway, New Jersey-based company is now forecasting 2023 sales of $57.7 billion to $58.9 billion, slightly higher than the $57.2 to $58.7 billion guidance provided in early February. The lifted guidance includes approximately $1 billion in sales of molnupiravir.
The company also raised its full-year adjusted earnings outlook to $6.88 to $7.00 per share, from a previous forecast of $6.80 to $6.95 per share.
The forecast does not reflect any financial impact from Merck’s proposed acquisition of biotech company Prometheus Biosciences earlier this month, the company noted. Merck said that deal is expected to close in the third quarter of 2023.
Merck’s molnupiravir treatment first entered the market after the…
Read the full article here